MCID: FLL027
MIFTS: 63

Fallopian Tube Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

MalaCards integrated aliases for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 55 15 73
Fallopian Tube Cancer 12 53 37 55 15
Cancer of the Fallopian Tube 12 53
Neoplasm of Fallopian Tube 12 29
Fallopian Tube Neoplasms 44 73
Malignant Neoplasm of Fallopian Tube 73
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 59
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Carcinoma of Fallopian Tube 12
Tumor of the Fallopian Tube 12
Cancer of Fallopian Tubes 59
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 59
Fallopian Tube Ca 12
Tubal Cancer 59

Characteristics:

Orphanet epidemiological data:

59
malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
MeSH 44 D005185
SNOMED-CT 68 93794008
ICD10 33 C57.0
ICD9CM 35 183.2
Orphanet 59 ORPHA180242
UMLS via Orphanet 74 C0153579 C0238122
ICD10 via Orphanet 34 C57.0
KEGG 37 H01554

Summaries for Fallopian Tube Carcinoma

NIH Rare Diseases : 53 Fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus. It is very rare and accounts for only 1-2% of all gynecologic cancers.  Fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor. Cancer can begin in any of the different cell types that make up the fallopian tubes. The most common type is called adenocarcinoma (a cancer of cells from glands). Leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare.  While some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. For example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon.  Women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. The signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. Signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. Doctors use many tests to diagnose cancer of the fallopian tubes. Some of these tests may include: pelvic examination, transvaginal ultrasound, a blood test that measures the tumor marker CA-125, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Fallopian tube cancer can be best treated when detected early. If the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. The stage of the cancer determines the type of treatment needed. Most women will need surgery and some will go on to have chemotherapy and/or radiation therapy.

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to fallopian tube adenocarcinoma and tuberculous salpingitis. An important gene associated with Fallopian Tube Carcinoma is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and GPCR Pathway. The drugs Olaparib and Poly(ADP-ribose) Polymerase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include fallopian tube, ovary and breast, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Disease Ontology : 12 A female reproductive organ cancer that is located in fallopian tube.

Wikipedia : 76 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases in the Fallopian Tube Carcinoma family:

Fallopian Tube Benign Neoplasm

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 fallopian tube adenocarcinoma 31.9 BRCA1 BRCA2 ERBB2
2 tuberculous salpingitis 30.4 BRCA1 BRCA2 ERBB2
3 endometriosis of ovary 30.4 ESR1 PGR
4 carcinosarcoma 30.3 ERBB2 PGR TP53
5 uterine carcinosarcoma 30.0 ERBB2 PGR TP53
6 endometriosis 30.0 ESR1 PGR VEGFA
7 inflammatory breast carcinoma 29.9 ERBB2 ESR1 PGR
8 adenocarcinoma 29.8 ERBB2 MYC TP53 VEGFA
9 ovarian cancer 1 29.8 BRCA1 BRCA2 ERBB2 TP53 VEGFA
10 estrogen-receptor positive breast cancer 29.7 ERBB2 ESR1 PGR TP53
11 primary peritoneal carcinoma 29.3 BRCA1 BRCA2 ERBB2 PGR TP53 VEGFA
12 ovarian cancer 28.9 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
13 breast cancer 28.5 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
14 familiar fallopian tube carcinoma 12.3
15 fallopian tube adenosarcoma 11.2
16 fallopian tube transitional cell carcinoma 11.2
17 fallopian tube squamous cell carcinoma 11.2
18 fallopian tube leiomyosarcoma 11.2
19 fallopian tube carcinosarcoma 11.2
20 fallopian tube germ cell cancer 11.2
21 ovary adenocarcinoma 10.3 ERBB2 TP53
22 esophagus adenocarcinoma 10.3 ERBB2 TP53
23 barrett's adenocarcinoma 10.3 ERBB2 TP53
24 tonsil cancer 10.3 ERBB2 TP53
25 granulosa cell tumor of the ovary 10.3 ERBB2 TP53
26 breast secretory carcinoma 10.2 ERBB2 PGR
27 acinar cell carcinoma 10.2 BRCA2 TP53
28 salpingitis 10.2
29 gastric papillary adenocarcinoma 10.2 ERBB2 TP53
30 endometrium carcinoma in situ 10.2 PGR TP53
31 lynch syndrome i 10.2 BRCA1 BRCA2
32 fanconi anemia, complementation group q 10.2 BRCA1 BRCA2
33 fallopian tube disease 10.2 BRCA1 BRCA2
34 scirrhous adenocarcinoma 10.2 ERBB2 PGR
35 gastric lymphoma 10.2 TP53 VEGFA
36 pleomorphic adenoma carcinoma 10.2 ERBB2 TP53
37 breast apocrine carcinoma 10.2 ERBB2 PGR
38 pancreatic ductal carcinoma 10.2 TP53 VEGFA
39 soft tissue sarcoma 10.2 TP53 VEGFA
40 non-proliferative fibrocystic change of the breast 10.2 ERBB2 TP53
41 wallerian degeneration 10.2 ERBB2 VEGFA
42 intracystic papillary adenoma 10.2 ERBB2 PGR
43 breast metaplastic carcinoma 10.2 ERBB2 PGR
44 hereditary site-specific ovarian cancer syndrome 10.2 BRCA1 BRCA2
45 progesterone-receptor negative breast cancer 10.2 ERBB2 PGR
46 breast malignant phyllodes tumor 10.2 PGR TP53
47 breast squamous cell carcinoma 10.2 ERBB2 TP53
48 angiomatous meningioma 10.2 PGR VEGFA
49 olfactory groove meningioma 10.2 PGR TP53
50 breast reconstruction 10.2 BRCA1 BRCA2

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:



Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 9.93 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 9.93 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 9.93 BRCA1 BRCA2 PGR PSMB4
4 Decreased homologous recombination repair frequency GR00236-A-2 9.93 BRCA1 BRCA2 PGR PSMB4
5 Decreased homologous recombination repair frequency GR00236-A-3 9.93 BRCA1 BRCA2
6 Increased cell death HMECs cells GR00103-A-0 9.26 BRCA1 MYC PGR TP53
7 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
2 cellular MP:0005384 10.19 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
3 embryo MP:0005380 10.17 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
4 endocrine/exocrine gland MP:0005379 10.16 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
5 cardiovascular system MP:0005385 10.14 BRCA1 ERBB2 ESR1 MYC PGR TP53
6 homeostasis/metabolism MP:0005376 10.13 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
7 digestive/alimentary MP:0005381 10.12 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
8 integument MP:0010771 10.1 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
9 growth/size/body region MP:0005378 10.09 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
10 hematopoietic system MP:0005397 10.08 BRCA1 BRCA2 ESR1 MYC PGR TP53
11 limbs/digits/tail MP:0005371 10.08 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
12 mortality/aging MP:0010768 10.06 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
13 immune system MP:0005387 10.05 BRCA1 BRCA2 ESR1 MYC PGR TP53
14 neoplasm MP:0002006 10.01 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
15 muscle MP:0005369 9.98 BRCA1 ERBB2 ESR1 MYC PGR TP53
16 nervous system MP:0003631 9.91 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
17 normal MP:0002873 9.86 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
18 reproductive system MP:0005389 9.76 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
19 no phenotypic analysis MP:0003012 9.72 ESR1 MYC PGR TP53 VEGFA
20 respiratory system MP:0005388 9.35 BRCA1 ERBB2 ESR1 TP53 VEGFA
21 skeleton MP:0005390 9.23 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 383)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
2 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
5
Mechlorethamine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 51-75-2 4033
6
Ifosfamide Approved Phase 2, Phase 3,Phase 3 3778-73-2 3690
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
10
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
11
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
16
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Niraparib Approved, Investigational Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
19
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
20
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
21
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
22
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
25
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
26
Rucaparib Approved, Investigational Phase 3,Phase 1,Phase 2 283173-50-2 9931954
27
Nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
29
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
31
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 56-86-0 33032
32
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
33
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
34
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
35
Trebananib Investigational Phase 3,Phase 2,Phase 1 894356-79-7
36
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
37 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
38
Maleic acid Experimental Phase 2, Phase 3,Phase 3,Phase 1 110-16-7 444266
39
Fosbretabulin Investigational Phase 2, Phase 3 222030-63-9 5351387
40 Combretastatin Investigational Phase 2, Phase 3 82855-09-2
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
44
Isophosphamide mustard Phase 2, Phase 3,Phase 3 0
45 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
46 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
47 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
48 Antimetabolites Phase 3,Phase 2,Phase 1
49 Antiviral Agents Phase 3,Phase 2,Phase 1
50 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 618)
# Name Status NCT ID Phase Drugs
1 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
2 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
3 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
4 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
5 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
6 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
7 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
8 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
10 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
11 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
12 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
13 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
14 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
15 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
16 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
17 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
18 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
19 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
20 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
21 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
22 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
23 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
24 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
25 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
26 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
27 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
28 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
29 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
30 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
31 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
32 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
33 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
34 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
35 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient Recruiting NCT03705156 Phase 3 ZL-2306(nirapairb);Placebos
38 Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 Recruiting NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
39 Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer Recruiting NCT03717610 Phase 3
40 A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer Recruiting NCT03709316 Phase 3 ZL-2306 (Nirapairb);Placebo Comparator
41 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib
42 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
43 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
44 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
45 A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. Recruiting NCT03106987 Phase 3 Active Comparator: Olaparib tablets;Placebo
46 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients Recruiting NCT03402841 Phase 3 Olaparib
47 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
48 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03635489 Phase 3 Paclitaxel;Bevacizumab;Carboplatin;Placebo
49 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
50 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3

Search NIH Clinical Center for Fallopian Tube Carcinoma

Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 29

Anatomical Context for Fallopian Tube Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Carcinoma:

19
Fallopian Tube

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

41
Ovary, Breast, Testes, Colon, Smooth Muscle, Uterus, Appendix

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show top 50) (show all 322)
# Title Authors Year
1
Port-site metastasis as a primary complication following diagnostic laparoscopy of fallopian tube carcinoma: A case report. ( 29952964 )
2018
2
Successful diagnosis of an occult fallopian tube carcinoma detected from the diaphragm metastasis. ( 29327265 )
2018
3
The Sign of Leser-Trelát and Malignant Acanthosis Nigricans Associated With Fallopian Tube Carcinoma. ( 30303917 )
2018
4
Magnetic resonance diffusion-weighted imaging in diagnostics of primary fallopian tube carcinoma - is it useful? ( 30038695 )
2018
5
Prognostic factors of primary fallopian tube carcinoma. ( 30150886 )
2018
6
MRI findings for primary fallopian tube cancer: correlation with pathological findings. ( 29151178 )
2018
7
Metastatic Fallopian Tube Cancer Detected During Colonoscopy. ( 29730436 )
2018
8
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). ( 29739622 )
2018
9
Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women. ( 29982601 )
2018
10
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer. ( 28247011 )
2017
11
Triple Synchronous Malignancies in Genital Tract; Primary Endometrial, Ovarian and Fallopian Tube Carcinoma: A Case Report. ( 28274004 )
2017
12
Evaluation of Short-Term Efficacy of Concurrent Chemoradiotherapy in Primary Fallopian Tube Carcinoma by Diffusion-Weighted Imaging: A Retrospective Study. ( 28423375 )
2017
13
Skin metastases in epithelial ovarian and fallopian tube carcinoma. ( 28816970 )
2017
14
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. ( 28698009 )
2017
15
Identifying features of primary fallopian tube carcinoma using magnetic resonance imaging. ( 28721103 )
2017
16
Primary Fallopian Tube Carcinoma: A Case Report and Literature Review. ( 28698755 )
2017
17
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. ( 28089376 )
2017
18
Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the "Komiyama's maneuver", a modification of Kocher's maneuver. ( 28237617 )
2017
19
Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement. ( 28389043 )
2017
20
Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer Patients ( 29172280 )
2017
21
Response to comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122290 )
2016
22
Associations of Promoter Methylations and mRNA Expressions of MMP-2, MMP-7 and MMP-9 with Primary Fallopian Tube Carcinoma. ( 26785083 )
2016
23
Comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122289 )
2016
24
Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 26712194 )
2016
25
Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study. ( 26825825 )
2016
26
Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery. ( 27976970 )
2016
27
Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. ( 27307153 )
2016
28
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. ( 27142770 )
2016
29
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. ( 26616225 )
2016
30
Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. ( 27206282 )
2016
31
Laparoscopic Restaging Surgery for Ovarian or Fallopian Tube Cancer. ( 27981938 )
2016
32
Primary fallopian tube carcinoma: correlation between magnetic resonance and diffuse weighted imaging characteristics and histopathologic findings. ( 25373473 )
2015
33
Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma. ( 25846583 )
2015
34
Robotic resection of bulky aorto-caval lymphadenopathy in a patient with serous fallopian tube carcinoma. ( 25449567 )
2015
35
Clinically Occult Primary Fallopian Tube Carcinoma Presenting as a Malignant Pleural Effusion. ( 26646473 )
2015
36
Primary fallopian tube carcinoma--a retrospective analysis of 66 cases. ( 26050354 )
2015
37
Management of Fallopian Tube Cancer. ( 26411954 )
2015
38
Primary fallopian tube carcinoma: review of MR imaging findings. ( 26150249 )
2015
39
Fallopian Tube Cancer with Palmar Fibromatosis or Fasciitis without Polyarthritis. ( 26370871 )
2015
40
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. ( 26180927 )
2015
41
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia. ( 25895616 )
2015
42
Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. ( 26111788 )
2015
43
Magnetic resonance imaging features of fallopian tube carcinoma. ( 25890392 )
2015
44
Metastatic fallopian tube carcinoma presenting as an inguinal hernia. ( 25675933 )
2015
45
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. ( 26456812 )
2015
46
Prognostic Significance of Retroperitoneal Lymphadenectomy, Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Primary Fallopian Tube Carcinoma: A Multicenter Study. ( 25622588 )
2015
47
MRI for differentiating primary fallopian tube carcinoma from epithelial ovarian cancer. ( 25176611 )
2015
48
Videolaparoscopy Debulking Lymphadenectomy in a Fallopian Tube Cancer Patient. ( 27678804 )
2015
49
Surgical diagnosis of stage I fallopian tube cancer in anti-Yo antibody paraneoplastic cerebellar degeneration. ( 24960213 )
2014
50
Prognostic factors of primary fallopian tube cancer in a single institute in Taiwan. ( 24997471 )
2014

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 457)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6938356 ZFHX3 large intestine,appendix,carcinoma,adenocarcinoma c.3122A>C p.K1041T 16:72950563-72950563 6
2 COSM6933903 XIAP large intestine,appendix,carcinoma,adenocarcinoma c.591A>T p.Q197H 23:123886253-123886253 6
3 COSM6976113 WT1 large intestine,appendix,carcinoma,adenocarcinoma c.463G>A p.D155N 11:32428599-32428599 6
4 COSM6904337 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 6
5 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 6
6 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 17:7674241-7674241 6
7 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 17:7675223-7675223 6
8 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 6
9 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 6
10 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 17:7674269-7674269 6
11 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 6
12 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 6
13 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 6
14 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 6
15 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 6
16 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
17 COSM6932 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 17:7674230-7674230 6
18 COSM10648 TP53 endometrium,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 6
19 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
20 COSM10656 TP53 endometrium,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 6
21 COSM43596 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 17:7673779-7673779 6
22 COSM10659 TP53 endometrium,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 17:7673803-7673803 6
23 COSM44944 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.451C>G p.P151A 17:7675161-7675161 6
24 COSM10645 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.527G>T p.C176F 17:7675085-7675085 6
25 COSM10808 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.488A>G p.Y163C 17:7675124-7675124 6
26 COSM11286 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.1015G>T p.E339* 17:7670694-7670694 6
27 COSM10863 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.833C>T p.P278L 17:7673787-7673787 6
28 COSM43955 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.514G>A p.V172I 17:7675098-7675098 6
29 COSM10662 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 6
30 COSM10794 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.796G>A p.G266R 17:7673824-7673824 6
31 COSM12193 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.668C>T p.P223L 17:7674863-7674863 6
32 COSM44093 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.644G>A p.S215N 17:7674887-7674887 6
33 COSM43872 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.560-1G>C p.? 17:7674972-7674972 6
34 COSM6901 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.559+1G>A p.? 17:7675052-7675052 6
35 COSM44388 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.853G>T p.E285* 17:7673767-7673767 6
36 COSM11183 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.799C>T p.R267W 17:7673821-7673821 6
37 COSM10883 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.731G>A p.G244D 17:7674232-7674232 6
38 COSM6954252 TOP1 large intestine,appendix,carcinoma,adenocarcinoma c.1303A>G p.I435V 20:41101348-41101348 6
39 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 6
40 COSM2983542 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1582C>G p.R528G 3:30691477-30691477 6
41 COSM33076 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1583G>A p.R528H 3:30691478-30691478 6
42 COSM6938933 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1069G>T p.G357W 3:30672252-30672252 6
43 COSM6503127 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.155A>C p.K52T 3:30644807-30644807 6
44 COSM6967188 TCF7L2 large intestine,appendix,carcinoma,adenocarcinoma c.1760C>T p.P587L 10:113165941-113165941 6
45 COSM6083762 STK11 large intestine,appendix,carcinoma,adenocarcinoma c.752G>T p.G251V 19:1221230-1221230 6
46 COSM6932862 STAT3 large intestine,appendix,carcinoma,adenocarcinoma c.365C>T p.A122V 17:42345566-42345566 6
47 COSM6938938 SPOP large intestine,appendix,carcinoma,adenocarcinoma c.413G>A p.R138H 17:49619048-49619048 6
48 COSM4067486 SPOP large intestine,appendix,carcinoma,adenocarcinoma c.295C>T p.R99W 17:49619291-49619291 6
49 COSM6982254 SOX9 large intestine,appendix,carcinoma,adenocarcinoma c.613A>T p.K205* 17:72122900-72122900 6
50 COSM2719086 SOX17 large intestine,appendix,carcinoma,adenocarcinoma c.329C>T p.T110M 8:54459079-54459079 6

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 BRCA1 ERBB2 ESR1 MYC PGR PSMB4
2
Show member pathways
13.54 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
3
Show member pathways
13.37 BRCA1 ERBB2 MYC PSMB4 TP53 VEGFA
4
Show member pathways
13.26 BRCA1 BRCA2 MYC PSMB4 TP53
5
Show member pathways
13.2 ERBB2 MYC PSMB4 TP53 VEGFA
6
Show member pathways
12.85 BRCA1 ERBB2 MYC TP53 VEGFA
7
Show member pathways
12.73 BRCA2 ERBB2 MYC TP53 VEGFA
8
Show member pathways
12.68 BRCA1 ESR1 MYC PSMB4 TP53
9 12.63 ERBB2 MYC TP53 VEGFA
10 12.63 BRCA2 ERBB2 ESR1 MYC TP53 VEGFA
11
Show member pathways
12.47 BRCA1 BRCA2 ERBB2 ESR1 TP53 VEGFA
12
Show member pathways
12.37 ERBB2 MYC TP53 VEGFA
13 12.37 BRCA1 ERBB2 MYC TP53 VEGFA
14
Show member pathways
12.34 BRCA1 BRCA2 ESR1 MYC PSMB4 TP53
15
Show member pathways
12.28 BRCA1 ESR1 VEGFA
16
Show member pathways
12.25 BRCA1 MYC TP53
17
Show member pathways
12.17 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
18
Show member pathways
12.13 BRCA1 PSMB4 TP53
19
Show member pathways
12.08 ERBB2 MYC TP53
20
Show member pathways
12.08 BRCA1 ESR1 MYC PGR
21 12.07 ERBB2 ESR1 MYC TP53 VEGFA
22 12.06 MYC TP53 VEGFA
23 12.02 ERBB2 MYC TP53
24 11.93 PSMB4 TP53 VEGFA
25 11.9 ESR1 MYC TP53
26 11.88 ERBB2 MYC TP53
27 11.88 MYC TP53 VEGFA
28
Show member pathways
11.85 ERBB2 ESR1 PGR
29
Show member pathways
11.75 ERBB2 ESR1 MYC VEGFA
30
Show member pathways
11.73 BRCA1 BRCA2 TP53
31 11.67 BRCA1 ERBB2 TP53
32 11.62 ERBB2 MYC TP53 VEGFA
33 11.59 ERBB2 MYC TP53
34 11.58 PSMB4 TP53 VEGFA
35 11.56 BRCA1 ERBB2 MYC
36 11.52 BRCA1 ERBB2 MYC TP53
37 11.47 BRCA1 BRCA2 TP53
38 11.44 ESR1 MYC VEGFA
39 11.41 BRCA1 MYC TP53
40 11.39 BRCA1 MYC TP53
41 11.35 ESR1 MYC TP53
42 11.29 ESR1 TP53
43 11.29 BRCA1 BRCA2 ESR1 MYC TP53 VEGFA
44 11.28 TP53 VEGFA
45 11.27 BRCA2 ESR1 MYC
46 11.26 ESR1 TP53
47 11.23 MYC TP53
48 11.21 BRCA1 TP53
49 11.19 BRCA1 TP53
50 11.16 BRCA1 TP53

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.8 BRCA1 BRCA2 ESR1 MYC PGR PSMB4
2 cytoplasm GO:0005737 9.61 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
3 nuclear chromatin GO:0000790 9.5 ESR1 MYC TP53
4 lateral element GO:0000800 9.16 BRCA1 BRCA2
5 protein-containing complex GO:0032991 9.02 BRCA1 BRCA2 ESR1 MYC TP53

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.97 BRCA1 ERBB2 ESR1 MYC VEGFA
2 negative regulation of apoptotic process GO:0043066 9.87 ERBB2 MYC TP53 VEGFA
3 cellular response to DNA damage stimulus GO:0006974 9.85 BRCA1 BRCA2 MYC TP53
4 positive regulation of transcription, DNA-templated GO:0045893 9.8 BRCA1 BRCA2 ESR1 MYC TP53
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 BRCA1 ESR1 MYC PGR TP53 VEGFA
6 transcription, DNA-templated GO:0006351 9.79 ESR1 MYC PGR
7 cell proliferation GO:0008283 9.78 BRCA2 ERBB2 MYC TP53
8 negative regulation of gene expression GO:0010629 9.73 ESR1 MYC PGR VEGFA
9 cellular response to hypoxia GO:0071456 9.7 MYC TP53 VEGFA
10 response to estradiol GO:0032355 9.67 BRCA2 ESR1 MYC
11 positive regulation of gene expression GO:0010628 9.65 BRCA1 ERBB2 MYC TP53 VEGFA
12 mammary gland development GO:0030879 9.63 BRCA2 PGR
13 positive regulation of epithelial cell proliferation GO:0050679 9.63 ERBB2 MYC VEGFA
14 negative regulation of fibroblast proliferation GO:0048147 9.62 MYC TP53
15 chromosome organization GO:0051276 9.61 BRCA2 MYC
16 cell aging GO:0007569 9.61 BRCA2 TP53
17 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.6 BRCA2 TP53
18 positive regulation of cell cycle arrest GO:0071158 9.59 BRCA1 TP53
19 positive regulation of mesenchymal cell proliferation GO:0002053 9.58 MYC VEGFA
20 mammary gland alveolus development GO:0060749 9.56 ESR1 VEGFA
21 cellular response to estrogen stimulus GO:0071391 9.54 ESR1 MYC
22 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.51 ESR1 TP53
23 chordate embryonic development GO:0043009 9.37 BRCA1 BRCA2
24 protein deubiquitination GO:0016579 9.35 BRCA1 ESR1 MYC PSMB4 TP53
25 response to gamma radiation GO:0010332 9.33 BRCA2 MYC TP53
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.8 BRCA1 BRCA2 ESR1 MYC PGR TP53
2 protein heterodimerization activity GO:0046982 9.56 ERBB2 MYC TP53 VEGFA
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.46 ESR1 MYC PGR TP53
4 steroid binding GO:0005496 9.37 ESR1 PGR
5 enzyme binding GO:0019899 9.26 BRCA1 ESR1 PGR TP53
6 identical protein binding GO:0042802 9.17 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53

Sources for Fallopian Tube Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....